MAIA Biotechnology, Inc. (MAIA) - Dilution Analysis

10-Q filing | 60.8M shares outstanding

8-K filing: MAIA Biotechnology, Inc. entered into a Securities Purchase Agreement for the issuance and sale of common stock and warrants in a private placement. ($1.51M proceeds)

10-Q filing | 37.0M shares outstanding

8-K filing: MAIA Biotechnology, Inc. entered into a Securities Purchase Agreement for the issuance and sale of 603,769 shares of common stock and warrants to purchase up to 603,769 shares of common stock at a price of $1.22 per share, for gross proceeds of approximately $736,600. ($0.74M proceeds)

8-K filing: MAIA Biotechnology, Inc. entered into a Securities Purchase Agreement for the issuance and sale of 1,733,766 shares of common stock and warrants to purchase up to 1,733,766 shares of common stock at a price of $1.30 per share. ($2.25M proceeds)

8-K filing: MAIA Biotechnology, Inc. entered into inducement offer letter agreements with accredited investors to exercise warrants for 440,503 shares of common stock at a reduced exercise price of $1.30 per share, with expected gross proceeds of $572,654. ($0.57M proceeds)

10-Q filing | 30.3M shares outstanding

8-K filing: MAIA Biotechnology, Inc. entered into a stock purchase agreement with Prevail Partners, LLC to issue and sell Shares of common stock for $587,905, with payments structured as an upfront payment and thirty-six equal tranche payments, subject to a minimum share price of $1.74 and a 19.99% blocker. ($0.59M proceeds)

8-K filing: MAIA Biotechnology, Inc. entered into inducement offer letter agreements with accredited investors to exercise warrants for 219,283 shares of common stock at a reduced exercise price of $1.50 per share, resulting in gross proceeds of approximately $328,925 for the Company. ($0.33M proceeds)

8-K filing: MAIA Biotechnology, Inc. entered into a Securities Purchase Agreement for a private placement involving the issuance and sale of common stock and warrants to accredited investors and a director, with expected gross proceeds of approximately $695,000. ($0.7M proceeds)

10-Q filing | 27.7M shares outstanding

8-K filing: MAIA Biotechnology, Inc. entered into a Securities Purchase Agreement for the issuance and sale of 633,333 shares of common stock and warrants to purchase up to 633,333 shares at $1.50 per share, along with director participation for 86,667 shares and warrants, totaling approximately $1.08 million in gross proceeds for funding a Phase II trial and working capital. ($1.08M proceeds)

10-K filing | 29.6M shares outstanding

8-K filing: MAIA Biotechnology, Inc. entered into a Securities Purchase Agreement for a private placement involving the issuance and sale of 894,300 shares of common stock and warrants to purchase up to 894,300 shares of common stock to accredited investors, and 58,333 shares of common stock and warrants to purchase up to 58,333 shares of common stock to Company directors, at a price of $1.50 per share. ($1.43M proceeds)

8-K filing: MAIA Biotechnology, Inc. entered into a Securities Purchase Agreement for a private placement involving the issuance of common stock and warrants to accredited investors and members of the board of directors, with gross proceeds expected to be approximately $2.715 million. ($2.72M proceeds)

10-Q filing | 23.9M shares outstanding

10-Q filing | 22.2M shares outstanding

10-Q filing | 21.8M shares outstanding

10-K filing | 20.0M shares outstanding

10-Q filing | 13.7M shares outstanding

S-3 filing: MAIA Biotechnology, Inc. files an S-3 form to register a shelf offering of common stock, preferred stock, debt securities, subscription rights and warrants with an aggregate offering price not to exceed $150,000,000.

10-Q filing | 12.9M shares outstanding

RW filing: This is a request to withdraw the registration statement on Form S-1 (File No. 333-272524) because the company is not currently pursuing a public offering of securities.

S-1 filing: This is an S-1 filing for MAIA Biotechnology, Inc. offering 2,083,333 shares of common stock at an assumed price of $2.40 per share.

10-Q filing | 13.6M shares outstanding

8-K filing: MAIA Biotechnology, Inc. consummated a public offering of 2,555,500 shares of common stock at $2.25 per share, resulting in net proceeds of approximately $5.1 million, and also issued warrants to purchase 127,775 shares to the Representative. ($5.1M proceeds)

S-1/A filing: MAIA Biotechnology, Inc. is offering 1,416,430 shares of its common stock at an assumed public offering price of $3.53 per share, and pre-funded warrants to purchase 1,416,430 shares of its common stock.

S-1/A filing: MAIA Biotechnology, Inc. is offering 3,191,489 shares of its common stock at an assumed public offering price of $3.76 per share, and pre-funded warrants to purchase 3,191,489 shares of its common stock.

S-1/A filing: The filing relates to an S-1/A filing for 3,360,000 shares of common stock at an assumed offering price of $3.57 per share.

10-K filing | 11.0M shares outstanding

S-1 filing: This S-1 filing is for an offering of 2,430,000 shares of common stock at an assumed offering price of $4.73 per share. It also includes an over-allotment option for the underwriters to purchase up to an additional 364,500 shares.

10-Q filing | 10.2M shares outstanding

10-Q filing | 10.9M shares outstanding

8-K filing: MAIA Biotechnology, Inc. completed an initial public offering of 2,000,000 shares of common stock at $5.00 per share, resulting in net proceeds of $9.25 million, and issued warrants to purchase 100,000 shares to the underwriter. ($10.0M proceeds)

S-1/A filing: MAIA Biotechnology, Inc. is offering 1,666,667 shares of common stock with an expected initial public offering price between $5.00 and $7.00 per share. The underwriters have a 45-day option to purchase up to an additional 250,000 shares of common stock.

S-1/A filing: MAIA Biotechnology, Inc. is offering 1,666,667 shares of common stock in an initial public offering, with an expected price between $5.00 and $7.00 per share. The underwriters have a 45-day option to purchase up to an additional 250,000 shares.

S-1/A filing: MAIA Biotechnology, Inc. is filing an S-1/A for shares of common stock. They have applied to have their common stock listed on the NYSE American under the symbol "MAIA."

S-1/A filing: MAIA Biotechnology, Inc. is offering common stock, with the intention to use the net proceeds from this offering, along with our existing cash and cash equivalents, to fund the planned trials of THIO, pre-clinical development of second-generation of telomere targeting compounds and our other research and development activities, as well as for working capital and other general corporate purposes.

S-1 filing: MAIA Biotechnology, Inc. is filing an S-1 to offer shares of common stock. They have granted the underwriters a 45-day option to purchase additional shares. They intend to use the net proceeds from this offering, along with our existing cash and cash equivalents, to fund the planned trials of THIO, pre-clinical development of second-generation of telomere targeting compounds and our other research and development activities, as well as for working capital and other general corporate purposes.